Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients.

ABSTRACT:

Background

Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease.

Methods

Direct and indirect costs (based on self-reported information on healthcare utilization) and health-related quality of life (HRQL, as assessed by SGRQ, CAT, and EQ-5D-3 L) were compared between 131 AATD patients (106 with, 25 without augmentation therapy (AT)) and 2,049 COPD patients without AATD participating in the COSYCONET COPD cohort. The medication costs of AT were excluded from all analyses to reveal differences associated with morbidity profiles. The association of AATD (with/without AT) with costs or HRQL was examined using generalized linear regression modelling (GLM) adjusting for age, sex, GOLD grade, BMI, smoking status, education and comorbidities.

Results

SUBMITTER: Karl FM 

PROVIDER: S-EPMC5392996 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature